Dr. Jim Tananbaum is an entrepreneur in healthcare industry focusing on operational, strategic, and financial ventures. Armed with B.S.E.E, M.D, and M.B.A from Yale University, Harvard Medical School, and Harvard Business School respectively, Dr. Tananbaum is best equipped for the industry.
Dr. Tananbaum was named in Forbes Midas list of 2017 for three years running. This list acknowledges top 100 investors who take early chances to invest in high-tech companies and eventually creating enormous wealth to their investors.
In his lifetime Dr. Tananbaum has led a successful investment in healthcare companies naming Jazz, Amira and Amerigroup Pharmaceuticals and many others. He founded and managed GelTex (a company that bought two drugs for less than $ 80 million and now have an income of $1 billion) and Theravance Pharmaceuticals. Also, Tananbaum partnered in forming a successful investment group- prospect partner II and III.
Dr. Tananbaum is the architect behind and CEO of Foresite Capital. Foresite Capital is an investment organization in healthcare industry both in private and public sector. Foresite Capital has its base in San Francisco with other offices in New York. See Foresite Capital’s Linked In page here.
Recently Foresite Capital in partnership with ARCH partners, Optum Venture, and One Mind Brain Health Impact Fund ventured into $14 million project Series A round f. According to PatientDaily.com, the project involves Mindstrong Health platform that focuses on employing smartphones to diagnose and assist in neuropsychiatric treatment. For the correct assessment of cognitive function, individuals will scroll or type on their smartphone. The program will furnish data regarding the cognition and mood biomarkers processing speed, memory, attention, and function.
Regarding Mindstrong Health Program, Dr. Jim Tananbaum in a prepared statement expressed high optimism on the project. “Mindstrong Health Founding team brings unmatched understanding of the challenges surrounding the way the medical community cares for patients suffering from cognitive health disorders …. the innovative platform modernizes and vastly improves the way in which care is provided.”
Foresite Capital under the stewardship of Dr. Tananbaum is also planning to launch an ambitious project – Intarcia by the end of 2017, see google.com. Intarcia is a twice per year implant for type II diabetes which assists the patient to manage their diabetes and also lose weight.
Visit officialjimtananbaum.com for more info.